|会社名||Vertex Pharmaceuticals Inc. （バ―テックス・ファ―マシュ―ティカルズ）|
|分野（sector）||Health Care ヘルスケア|
|業種||バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care）|
|概要||事業概要 バーテックス・ファーマシューティカルズ（Vertex Pharmaceuticals Incorporated）は重篤な疾患の治療薬の発見・開発・生産・商品化に従事する会社である。同社は嚢胞性線維症（CF）の治療法の開発と商品化に注力し、他の適応症における研究開発プログラムの推進に取り組んでいる。同社の販売されている医薬品は、ORKAMBIおよびKALYDECOである。ORKAMBI（ivacaftorと組み合わせたlumacaftor）は、その嚢胞性線維症膜貫通コンダクタンス調節因子（CFTR）遺伝子にDelta-F508（F508del）突然変異を2コピー（同型接合）有する患者の治療薬として承認される。KALYDECO（ivacaftor）は、CFTR遺伝子にG551D突然変異または他の特定の突然変異を有するCF患者の治療のために承認されている。CF分野の開発プログラムには、Tezacaftor（VX-661）、VX-152、VX-440、VX-659、VX-445、VX-371などがあります。VX-152、VX-440、VX-659、VX-445はCFTR補正剤である。 バ―テックス・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。低分子薬品の発見、開発、製造、商業化に従事する。主要医薬品にはC型肝炎ウイルス治療薬「INCIVEK」と、嚢胞性線維症治療薬「KALYDECO」の2種類がある。その他、自己免疫疾患やインフルエンザ治療用の医薬品の開発にも従事。本社はボストン。 Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) - a rare, life-threatening genetic disease - and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of cell and genetic therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.|
|本社所在地||50 Northern Avenue Boston MA 02210 USA|
|代表者氏名||Jeffrey M. Leiden ジェフリー・M・ライデン|
|代表者役職名||Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO）|
|市場名||NASDAQ National Market System|
|決算概要||決算概要 BRIEF: For the six months ended 30 June 2018 Vertex Pharmaceuticals Incorporated revenues increased 11% to $1.39B. Net income applicable to common stockholders increased 57% to $417.5M. Revenues reflect Product revenues net increase of 40% to $1.39B. Net income benefited from Other income (expense) net increase from $3.1M (expense) to $150.7M (income) Restructuring expenses (income) decrease from $13.5M (expense) to $14K (income).|
Is Vertex Pharmaceuticals'' Billion-Dollar Business Getting Even Bigger? 2022/05/09 10:00:00 The Motley Fool
The company may extend its leadership in cystic fibrosis treatment.
Vertex: Q122 Results Solid, Pipeline Progress Makes Bull Case (NASDAQ:VRTX) 2022/05/06 23:23:27 Seeking Alpha
Vertex has a very strong cystic fibrosis franchise. Read more on how this company plans to grow its presence in this treatment area.
Vertex Pharmaceuticals Incorporated 2022 Q1 - Results - Earnings Call Presentation (NASDAQ:VRTX) 2022/05/06 20:03:27 Seeking Alpha
The following slide deck was published by Vertex Pharmaceuticals Incorporated in conjunction with their 2022 Q1 earnings call.
Vertex cut to neutral at Baird as stock fairly valued and no further upside seen (VRTX) 2022/05/06 13:02:20 Seeking Alpha
Baird has downgraded Vertex Pharmaceuticals (VRTX) to neutral from overweight saying that despite the company''s strong performance so far this year, there isn''t likely to be further upside.
Vertex Pharmaceuticals (VRTX) Q1 2022 Earnings Call Transcript 2022/05/06 06:03:02 The Motley Fool
VRTX earnings call for the period ending March 31, 2022.
Vertex Pharmaceuticals (NASDAQ:VRTX) Receives New Coverage from Analysts at Wells Fargo & Company 2021/12/11 08:44:42 Dakota Financial News
Wells Fargo & Company began coverage on shares of Vertex Pharmaceuticals (NASDAQ:VRTX) in a research note released on Wednesday, Price Targets.com reports. The firm issued an overweight rating and a $270.00 price objective on the pharmaceutical companys stock. Other equities analysts have also recently issued research reports about the company. Royal Bank of Canada lifted 
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Receives Average Rating of Buy from Brokerages 2021/12/11 00:56:42 Dakota Financial News
Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) have received a consensus rating of Buy from the twenty-three ratings firms that are covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell recommendation, five have given a hold recommendation and fourteen have issued a buy recommendation on the company. The average 
New York State Teachers Retirement System Trims Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) 2021/12/10 15:50:43 Dakota Financial News
New York State Teachers Retirement System lowered its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 3.8% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 328,526 shares of the pharmaceutical company’s stock after selling 13,108 shares during the quarter. New York State Teachers Retirement […]
Tekla World Healthcare Fund Buys Moderna Inc, Merck Inc, AstraZeneca PLC, Sells ResMed Inc, ... 2021/12/09 00:38:04 GuruFocus
Related Stocks: MRK , AZN , IDXX , GILD , CRL , PHG , MRNA , GH , QGEN , ALKS , BHVN , STVN , MTD , VRTX , QURE , ALXN , A , STE ,
Tekla Healthcare Opportunities Fund Buys Moderna Inc, IDEXX Laboratories Inc, Sarepta ... 2021/12/09 00:38:03 GuruFocus
Related Stocks: IDXX , SRPT , MOH , ZTS , AZN , LH , MRNA , GH , ICLR , JAZZ , RLYB , FUSN , VRTX , AMED , ALXN , CNC , INCY , IOVA ,
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Holdings Cut by Point72 Asset Management L.P. 2021/11/01 11:34:47 Transcript Daily
Point72 Asset Management L.P. lowered its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 90.0% during the second quarter, Holdings Channel reports. The firm owned 66,500 shares of the pharmaceutical companys stock after selling 597,473 shares during the period. Point72 Asset Management L.P.s holdings in Vertex Pharmaceuticals were worth $13,408,000 as of its most 
Analysts Estimate Report : What to Look Out for Vertex Pharmaceuticals (NASDAQ:VRTX) 2021/10/31 10:35:00 Stock Market Daily
Earnings results for Vertex Pharmaceuticals , Analyst Opinion on Vertex Pharmaceuticals , Earnings and Valuation of (NASDAQ:VRTX), Stock market Insights & financial analysis, Best stock to invest, Investment Idea, The post Analysts Estimate Report : What to Look Out for Vertex Pharmaceuticals (NASDAQ:VRTX) appeared first on .
Vertex and Mammoth Biosciences Ink $700M Deal for Ultra-Small CRISPR Systems 2021/10/29 19:14:47 JD Supra
Vertex Pharmaceuticals and Mammoth Biosciences, a Brisbane, California-based genetic research company, announced a new collaboration for the development of in vivo gene therapies for rare diseases using Mammoths ultra-small CRISPR systems. Over the past couple of years, Mammoth Biosciences, the brainchild of CRISPR pioneer and 2020 Nobel Prize Laureate Jennifer Doudna, has developed two super small Cas enzymes, which play a critical role in the cut-and-paste function of the CRISPR gene By: Rothwell, Figg, Ernst & Manbeck, P.C.
COVID-19: Moderna Gets Its Miracle 2021/10/29 16:15:00 Zero Hedge
COVID-19: Moderna Gets Its Miracle Authored by Whitney Webb via Unlimited Hangout , COVID-19 erased the regulatory and trial-related hurdles that Moderna could never surmount before. Yet, how did Moderna know that COVID-19 would create those conditions months before anyone else, and why did they later claim that their vaccine being tested in NIH trials was different than their commercial candidate? In late 2019, the biopharmaceutical company Moderna was facing a series of challenges that not only threatened its ability to ever take a product to market, and thus turn a profit, but its very existence as a company. There were multiple warning signs that Moderna was essentially another Theranos-style fraud, with many of these signs growing in frequency and severity as the decade drew to a close. Part I of this three-part series explored the disastrous circumstances in which Moderna found itself at that time, with the company’s salvation hinging on the hope of a divine miracle, a “Hail Mary” save of sorts, as stated by one former Moderna employee.
Experimental stem cell transplant promises reversal of type 1 diabetes 2021/10/29 13:26:03 Kenyan News
A new experimental stem cell-derived treatment (led by Vertex Pharmaceuticals) nearly reversed type 1 diabetes in a patient who had lived with the disease for nearly 40 years. The cells were delivered by infusion into the hepatic portal vein, and are the first to be transplanted to the liver. The therapy, using insulin-producing islet of […] Source: Experimental stem cell transplant promises reversal of type 1 diabetes
関連キーワード （バイオテクノロジ―_メディカルリサ―チ 米国株 バ―テックス・ファ―マシュ―ティカルズ VRTX Vertex Pharmaceuticals Incorporated）